Veoza, also known as fezolinetant, will be offered to women for whom HRT is unsuitable
More than 500,000 women in England are to be offered a drug on the NHS that prevents hot flushes.
The green light for Veoza, also known as fezolinetant, comes after the medicines watchdog, the National Institute for Health and Care Excellence, authorised it for use on Wednesday.
Hot flushes, also called vasomotor symptoms, affect about 70% of women going through menopause. Women can suddenly and overwhelmingly feel hot, which often has an impact on their quality of life, exercise, sleep and productivity.
Despite the enormous numbers of women affected, for decades there have been few safe and effective treatment options. Hormone replacement therapy (HRT) is the most effective, but this is unsuitable for many, such as some women with a history of breast or ovarian cancer, blood clots or with untreated high blood pressure. Some women experience side-effects or would prefer a non-hormonal alternative.
